Filgrastim is indicated for the prevention of neutropenia in patients undergoing chemotherapy; contraindications include hypersensitivity to filgrastim or E. coli-derived proteins; side effects may include bone pain, fatigue, and splenic rupture; drug interactions can occur with other myelosuppressive agents or medications that affect neutrophil function.